Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Net Income (2016 - 2024)

Trinity Biotech's Net Income history spans 16 years, with the latest figure at -$15.8 million for Q4 2024.

  • On a quarterly basis, Net Income fell 193.08% to -$15.8 million in Q4 2024 year-over-year; TTM through Dec 2025 was -$20.6 million, a 32.85% increase, with the full-year FY2025 number at -$37.4 million, down 6422.86% from a year prior.
  • Net Income hit -$15.8 million in Q4 2024 for Trinity Biotech, down from -$4.8 million in the prior quarter.
  • Over the last five years, Net Income for TRIB hit a ceiling of $10.7 million in Q3 2020 and a floor of -$18.3 million in Q2 2023.
  • Historically, Net Income has averaged -$4.1 million across 5 years, with a median of -$5.1 million in 2023.
  • Biggest five-year swings in Net Income: skyrocketed 511.27% in 2020 and later crashed 2026.0% in 2022.
  • Tracing TRIB's Net Income over 5 years: stood at $10.4 million in 2020, then tumbled by 132.48% to -$3.4 million in 2021, then tumbled by 210.31% to -$10.4 million in 2022, then soared by 48.38% to -$5.4 million in 2023, then crashed by 193.08% to -$15.8 million in 2024.
  • Business Quant data shows Net Income for TRIB at -$15.8 million in Q4 2024, -$4.8 million in Q3 2024, and -$6.9 million in Q2 2024.